detecting and treating breast cancer by providing a purified and isolated DNA binding protein that specifically binds to the promoter region of the c-ERBB2 (HER–2/neu) gene sequence (hence the term HER–2 promoter binding protein, HPBF). Antibodies specific for this DNA binding protein, called HPBF, can be used to assay for the presence of HPBF in a biological sample and, thus, detect the presence of cancer. The purified HPBF also can be used to test the ability of substances to inhibit the activity of HPBF and thus potentially halt or reverse growth of the cancer. This invention includes antisense nucleotides that effectively prevent HPBF from binding to the promoter. (portfolio: Cancer—Therapeutics, biological response modifiers, growth factors)

Acridone-Derived Bisintercalators as Chemotherapeutic Agents

Michejda, C.J., Cholody, W.M. Hernandez, L. (NCI)
Filed 14 Mar 94
Serial No. 08/213,315
Licensing Contact: Joseph Contrera, 301/496–7056 ext 244

This invention describes a noval class of acridone-derived intercalating agents that offer to improve the treatment of certain cancers. Presently available anti-tumor agents often have great toxicity for normal cells as well as tumor cells. Therefore, there is a great need for new chemotherapeutic agents that selectively kill tumor cells while sparing healthy cells. A number of acridine-based compounds have recently been discovered that exhibit high anti-tumor activity. This newly developed class of acridone-derived agents, which bind strongly to nucleic acids, have potent cytotoxic activity which is selective for solid tumor cells, especially for colon and prostatic tumors. Because some of these compounds exhibit enhanced fluorescence when bound to DNA, they also may be used in assays for the detection of DNA. (portfolio: Cancer—Therapeutics)

Dated: April 11, 1996.

Barbara M. McGarey,

Office of Technology Transfer.

[FR Doc. 96–9615 Filed 4–18–96; 8:45 am]

BILLING CODE 4140–01–M

Notice of Meeting of the NIH Director's Advisory Panel on Clinical Research

Notice is hereby given that the NIH Director's Advisory Panel on Clinical Research, a group reporting to the Advisory Committee to the Director (ACD), National Institutes of Health (NIH), will meet in public session in Wilson Hall, third floor of the Shannon Building (Building 1) National Institutes of Health, Bethesda, Maryland 20892, on May 16, 1996 from 8:30 a.m. until approximately noon.

The goal of the Panel is to review the status of clinical research in the United States, and to make recommendations to the ACD about how to ensure its effective continuance. Topics to be considered at this meeting are subcommittee progress reports and a discussion of the proposed NIH Clinical Research Center.

Attendance may be limited to seat availability. If you plan to attend the meeting as an observer or if you wish additional information, please contact Mrs. Janet Smith, National Institutes of Health, Building 10, Room 1C–116, 10 Center Drive, MSC 1154, Bethesda, Maryland 10892–1154, telephone (301) 402–3444, fax (301) 402–3443, by May 6, 1996. Individuals who plan to attend and need special assistance, such as sign language interpretation or other special accommodations, should contact Ms. Smith in advance of the meeting.

Dated: April 10, 1996.

Ruth L. Kirschstein,

Deputy Director, NIH.

[FR Doc. 96–9616 Filed 4–18–96; 8:45 am]

BILLING CODE 4140–01–M

Public Health Service

National Toxicology Program; National Toxicology Program (NTP) Board of Scientific Counselors' Biennial Report on Carcinogens (BRC) Subcommittee Meeting

Pursuant to Public Law 92–463, notice is hereby given of a meeting of the National Toxicology Program (NTP) Board of Scientific Counselors' Biennial Report on Carcinogens (BRC) Subcommittee, U.S. Public Health Service, in the Conference Center, Building 101, South Campus, National Institute of Environmental Health Sciences (NIEHS), 111 Alexander Drive, Research Triangle Park, North Carolina, on May 8, 1996.

The primary agenda topic will be concerned with the discussion of the process for listing or delisting substances in the Biennial Report on Carcinogens (BRC) (formerly Annual Report on Carcinogens (ARC)).

The preliminary agenda topics with approximate times are as follows:

8:30 a.m.–8:45 a.m.—Report of the Director, NTP
8:45 a.m.–9:00 a.m.—Report of the Director, Environmental Toxicology Program (ETP)
9:00 a.m.–10:00 a.m.—Report on the background history of the BRC
10:15 a.m.–11:15 a.m.—Presentation and discussion of the process for listing or delisting substances in the BRC
11:15 a.m.–11:35 a.m.—Report from the NIEHS/NTP BRC Review Group
11:35 a.m.–12:00 p.m.—Report from the NTP Executive Committee Working Group for the BRC
1:00 p.m. –2:00 p.m.—Subcommittee discussion of BRC presentations
2:00 p.m.–3:00 p.m.—Presentation of select chemicals previously approved for listing in the 8th and 9th BRC to compare application of proposed BRC criteria with previous ARC selection criteria
3:15 p.m.–4:30 p.m.—Subcommittee discussion of BRC review responsibilities
Adjournment

Public Comments Encouraged

The meeting is open to the public. A brief summary of the review of the BRC criteria for listing or delisting substances is available on request from the NTP Liaison Office, P.O. Box 12233, MD B3–01, Research Triangle Park, NC 27709, phone: (919) 541–0530, FAX: (919) 541–0295. Brief public oral comments will be allowed at appropriate times during the meeting. Registration to attend is not required; however, to ensure adequate seating, we ask that those planning to attend let us know. To register, receive information on the agenda, or be put on the mailing list for summary minutes subsequent to the meeting, please contact: Dr. L.G. Hart, P.O. Box 12233, Research Triangle Park, NC 27709; telephone: (919) 541–3971; FAX: (919) 541–0719.

Dated: April 12, 1996.

Kenneth Olden,

Director, National Toxicology Program.

[FR Doc. 96–9617 Filed 4–18–96; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–3917–N–66]

Office of the Assistant Secretary for Public and Indian Housing: Notice of Proposed Information Collection for Public Comment

AGENCY: Office of the Assistant Secretary for Public and Indian Housing, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below